PURPOSE: Somatic alterations have been shown to correlate with ovarian cancer prognosis and survival, but less is known about the effects on survival of common inherited genetic variation. Of particular interest are genes involved in cell cycle pathways, which regulate cell division and could plausibly influence clinical characteristics of multiple tumors types. EXPERIMENTAL DESIGN: We examined associations between common germ-line genetic variation in 14 genes involved in cell cycle pathway (CCND1, CCND2, CCND3, CCNE1, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDKN2D, CDK2, CDK4, CDK6, and RB1) and survival among women with invasive ovarian cancer participating in a multicenter case-control study from United Kingdom, Denmark, and United States. DNAs from up to 1,499 women were genotyped for 97 single-nucleotide polymorphisms that tagged the known common variants (minor allele frequency > or = 0.05) in these genes. The genotypes of each polymorphism were tested for association with survival by Cox regression analysis. RESULTS: A nominally statistically significant association between genotype and ovarian cancer survival was observed for polymorphisms in CCND2 and CCNE1. The per-allele hazard ratios (95% confidence intervals) were 1.16 (1.03-1.31; P = 0.02) for rs3217933, 1.14 (1.02-1.27; P = 0.024) for rs3217901, and 0.85 (0.73-1.00; P = 0.043) for rs3217862 in CCND2 and 1.39 (1.04-1.85; P = 0.033) for rs3218038 in CCNE1. However, these were not significant after adjusting for multiple hypothesis tests. CONCLUSION: It is unlikely that common variants in cell cycle pathways examined above associated with moderate effect in survival after diagnosis of ovarian cancer. Much larger studies will be needed to exclude common variants with small effects.
PURPOSE: Somatic alterations have been shown to correlate with ovarian cancer prognosis and survival, but less is known about the effects on survival of common inherited genetic variation. Of particular interest are genes involved in cell cycle pathways, which regulate cell division and could plausibly influence clinical characteristics of multiple tumors types. EXPERIMENTAL DESIGN: We examined associations between common germ-line genetic variation in 14 genes involved in cell cycle pathway (CCND1, CCND2, CCND3, CCNE1, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDKN2D, CDK2, CDK4, CDK6, and RB1) and survival among women with invasive ovarian cancer participating in a multicenter case-control study from United Kingdom, Denmark, and United States. DNAs from up to 1,499 women were genotyped for 97 single-nucleotide polymorphisms that tagged the known common variants (minor allele frequency > or = 0.05) in these genes. The genotypes of each polymorphism were tested for association with survival by Cox regression analysis. RESULTS: A nominally statistically significant association between genotype and ovarian cancer survival was observed for polymorphisms in CCND2 and CCNE1. The per-allele hazard ratios (95% confidence intervals) were 1.16 (1.03-1.31; P = 0.02) for rs3217933, 1.14 (1.02-1.27; P = 0.024) for rs3217901, and 0.85 (0.73-1.00; P = 0.043) for rs3217862 in CCND2 and 1.39 (1.04-1.85; P = 0.033) for rs3218038 in CCNE1. However, these were not significant after adjusting for multiple hypothesis tests. CONCLUSION: It is unlikely that common variants in cell cycle pathways examined above associated with moderate effect in survival after diagnosis of ovarian cancer. Much larger studies will be needed to exclude common variants with small effects.
Authors: Estrid V Høgdall; Susanne K Kjaer; Eva Glud; Lise Christensen; Jan Blaakaer; Jens Vuust; Johannes E Bock; Bent Norgaard-Pedersen; Claus K Hogdall Journal: Anticancer Res Date: 2003 Jul-Aug Impact factor: 2.480
Authors: Andrew J Li; Dimitry L Lerner; Maria-Emily R Gapuzan; Beth Y Karlan Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-12 Impact factor: 4.254
Authors: Ewa Joanna Majdak; Jaroslaw Debniak; Tomasz Milczek; Cees J Cornelisse; Peter Devilee; Janusz Emerich; Jacek Jassem; Geertruida Hendrika De Bock Journal: Cancer Date: 2005-09-01 Impact factor: 6.860
Authors: Y Ben David; A Chetrit; G Hirsh-Yechezkel; E Friedman; B D Beck; U Beller; G Ben-Baruch; A Fishman; H Levavi; F Lubin; J Menczer; B Piura; J P Struewing; B Modan Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: C Matthias; K Branigan; V Jahnke; K Leder; J Haas; J Heighway; P W Jones; R C Strange; A A Fryer; P R Hoban Journal: Clin Cancer Res Date: 1998-10 Impact factor: 12.531
Authors: Shadi Amininia; Mohammad Hashemi; Mahboubeh Ebrahimi; Mohammad Ali Mashhadi; Seyed Mehdi Hashemi; Mohsen Taheri; Saeid Ghavami Journal: Med Oncol Date: 2014-08-27 Impact factor: 3.064
Authors: Andrea Mann; Estrid Hogdall; Susan J Ramus; Richard A DiCioccio; Claus Hogdall; Lydia Quaye; Valerie McGuire; Alice S Whittemore; Mitul Shah; David Greenberg; Douglas F Easton; Bruce A J Ponder; Susanne Krüger Kjaer; Simon A Gayther; Deborah J Thompson; Paul D P Pharoah; Honglin Song Journal: Eur J Cancer Date: 2008-08-22 Impact factor: 9.162
Authors: Prema Peethambaram; Brooke L Fridley; Robert A Vierkant; Melissa C Larson; Kimberly R Kalli; Elaine A Elliott; Ann L Oberg; Kristin L White; David N Rider; Gary L Keeney; Julie M Cunningham; Lynn C Hartmann; Ellen L Goode Journal: Int J Mol Epidemiol Genet Date: 2011-05-02
Authors: Márk Híveš; Jana Jurečeková; Ján Kliment; Marián Grendár; Peter Kaplán; Róbert Dušenka; Daniel Evin; Marta Vilčková; Klaudia Híveš Holečková; Monika Kmeťová Sivoňová Journal: Cancer Genomics Proteomics Date: 2022 May-Jun Impact factor: 4.069